Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 113Breast Neoplasms 80Neoplasms 75Neoplasm Metastasis 63Colorectal Neoplasms 63Prostatic Neoplasms 59Recurrence 57Leukemia, Myeloid, Acute 55Pancreatic Neoplasms 54Ovarian Neoplasms 53Multiple Myeloma 52Melanoma 40Glioblastoma 40Squamous Cell Carcinoma of Head and Neck 33Lung Neoplasms 33Triple Negative Breast Neoplasms 31Lymphoma, Non-Hodgkin 31Precursor Cell Lymphoblastic Leukemia-Lymphoma 30Endometrial Neoplasms 30Carcinoma, Renal Cell 28Lymphoma 27Lymphoma, Large B-Cell, Diffuse 26Carcinoma, Hepatocellular 26Stomach Neoplasms 25Lymphoma, B-Cell 25Small Cell Lung Carcinoma 24Leukemia, Lymphocytic, Chronic, B-Cell 24Brain Neoplasms 24Advanced Solid Tumor 24Myelodysplastic Syndromes 23

Interventions

Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Pancreatic Cancer Non-resectable × 90 days × Clear all
NCT07575191 2026-06-12

Safety and Performance of a Novel Infusion Catheter System for Peri/Intratumoral Gemcitabine Delivery in Patients With Pancreatic Cancer

Smartwise Sweden AB

Phase 1/2 Recruiting
9 enrolled
Gastrointestinal

Pancreatic Cancer Non-resectable

Data powered by HemOnc (CC BY 4.0) Colophon âš¡